GlobeNewswire

Intesa Sanpaolo, Iberdrola, and Ryanair Among Big Winners on Institutional Investor's 2018 All-Europe Executive Team Rankings

Dela

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Airbus (France), Lonza Group (Switzerland), Nestlé (Switzerland), Allianz (Germany), Subsea 7 (United Kingdom), ASML Holding (Netherlands), Ryanair Holdings (Ireland) - swept their respective sectors, ranking first across the CEO, CFO, and investor relations categories.

More than 2,400 buy-side analysts, asset managers, and sell-side researchers at over 800 firms named the best chief executives, top CFOs, investor relations professionals, and investor relations companies across 31 business sectors.

Buy-side analysts, money managers and sell-side researchers at securities firms and financial institutions that cover the region identified up to four companies that excel in up to seven investor relations attributes including:

  • Senior executives are accessible
  • IR team is well informed and empowered to speak authoritatively on the company's behalf
  • Timely and appropriate level of financial disclosure
  • Responds quickly and thoroughly to requests
  • Most constructive conference calls
  • Highest quality of meetings through road shows/reversed road shows/conferences; and highest quality of corporate documents and investor kit materials.

"MiFID II continues to drive change and create noise across the investment process for buy side, sell side and corporates, nowhere more so than in Europe. But this aside, this just continues to highlight the need to make sure companies are engaging smarter and more strategically with investors to ensure that their story is understood properly," says Will Rowlands-Rees, Managing Director of Research at Institutional Investor, "To that end we're thrilled with the continued depth of response from the European investment community on investor engagement, and are delighted to be working with many of Europe's leading companies to help be smarter and more discerning around their investor relations efforts. We'd like to congratulate all the recognized companies for their ongoing focus on excellence, and look forward to helping them construct and measure investor engagement programs in the year ahead."

Top Performing Companies and their Sectors Include:

Airbus (France) Aerospace & Defense
Allianz (Germany) Insurance
ASML Holding (Netherlands) Technology/Hardware
Iberdrola (Spain) Utilities
Intesa Sanpaolo (Italy) Banks
Lonza Group (Switzerland) Biotechnology
Nestlé (Switzerland) Food Producers
Ryanair Holdings (Ireland) Transport
Subsea 7 (United Kingdom) Oil Services

Top Performing CEOs and their Sectors Include:

Matthias Zachert LANXESS (Germany) Chemicals
Sergio Marchionne Fiat Chrysler Automobiles (United Kingdom) Autos & Auto Parts
Patrick Pouyanné Total (France) Oil & Gas Exploration & Production
Jean Pierre Mustier UniCredit (Italy) Banks
Thomas Enders Airbus (France) Aerospace & Defense
Richard Ridinger Lonza Group (Switzerland) Biotechnology
Martin Sorrell WPP (United Kingdom) Media

Top Performing CFOs and their Sectors Include:

Christopher Lynch Rio Tinto (United Kingdom) Metals & Mining
Felipe Dutra Anheuser-Busch InBev (Belgium) Beverages
Ricardo Rosa Subsea 7 (United Kingdom) Oil Services
Dieter Wemmer Allianz (Germany) Insurance
Brian May Bunzl (United Kingdom) Business & Employment Services
Peter Hackel Straumann Holding (Switzerland) Medical Technologies & Services
Wolfgang Nickl ASML Holding (Netherlands) Technology/Hardware

For the full list of published winners, please visit www.institutionalinvestor.com.

Last year, Institutional Investor launched its inaugural small and midcap rankings, recognizing those companies with less than $10bn in market capitalization to great success.  This year, a resounding set of feedback from 1,800 investment professionals demonstrated that investors continue to look for value beyond the largest companies, and that those companies are demonstrating strong capabilities in investor engagement to those investors. 

A total of 1,509 European companies were nominated in this year's All-Europe Executive Team rankings. Of those companies, 103 scored high enough to earn the distinction of Most Honored Company in the full sector rankings and 95 were honored in the midcap and small cap sector rankings.

For more information, please contact Amani Korayeim at amani.korayeim@institutionalinvestor.com  or + 44 207 779 8535.

To share your success in your website content, advertisements, communications, and marketing collateral, please contact PARS International Corp. online at www.ii-licensing.com

About Institutional Investor
For 51 years Institutional Investor has consistently distinguished itself among the world's foremost media companies with groundbreaking journalism and incisive writing that provides essential intelligence for a global audience. In addition, Institutional Investor offers a host of proprietary research and rankings that serve as respected industry benchmarks. For more information visit institutionalinvestor.com.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Institutional Investor News via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum